Pharmaceutical Market Europe • Novembe 2021 • 38-40
APPOINTMENTS
The European Medicines Group (EMG)
UDAY BOSE
Leading UK pharmaceutical industry group the European Medicines Group (EMG) has elected Uday Bose, managing director of Boehringer Ingelheim, as its new chair. He will be supported by vice-chairs, Pinder Sahota, general manager Novo Nordisk UK and Dan Coombes, general manager, Grünenthal UK. Bose said: “It is a privilege to be elected as chair of the European Medicines Group and in particular at this pivotal juncture for the UK. The pandemic has shown how effectively industry, the NHS and Government can work together when goals are aligned around the needs of patients and this approach should continue as we look to optimise post EU exit opportunities”. He added: “The EMG has an important role to play in this regard as we see the majority of Global investment directed towards those countries where the operating environment in terms of the appreciation of innovation is higher, as illustrated in the recently published Competitiveness Indicators.”
Alnylam
YVONNE GREENSTREET
Alnylam has appointed its president, Yvonne Greenstreet, as CEO. She succeeds John Maraganore, who remains as a member of the company’s Scientific Board. Greenstreet has 25 years’ experience in the Biopharmaceutical industry, having held senior positions with GSK and latterly Pfizer. She serves on the board of directors of Pacira Pharmaceuticals, argenyx and American Funds.
BioMarin
HAROLD BERNSTEIN
BioMarin has appointed Harold Bernstein as senior vice president, chief medical officer and head of clinical development. Bernstein has over 30 years’ experience, including senior roles with Vertex and Merck. He has also held appointments at the University of California San Francisco, Mount Sinai Kravis Children's Hospital and the Icahn School of Medicine at Mount Sinai.
ONA Therapeutics
HAIJUN SUN
ONA has appointed Haijun Sun as chief scientific officer. He has over 20 years’ experience and joins from GSK. He previously held senior positions at biotech companies in Europe and the US, including vice president of biological products at F-star Biotechnology, director of portfolio management at ImClone Systems and vice president of antibody development at Tizona Therapeutics.
Mogrify
LOUISE MODIS
Mogrify has appointed Louise Modis chief scientific officer. Modis has over 20 years’ experience in preclinical and clinical therapeutic research, having held a number of senior roles at GSK, including vice president of immunology research and representing GSK on the Sitryx board. Prior to GSK, she led research teams at Boehringer Ingelheim and Millennium Pharmaceuticals (now Takeda).
MiNA Therapeutics
TROELS KOCH
MiNA Therapeutics has appointed Troels Koch as senior vice president, chemistry to lead its chemistry research and strategy. He has over 20 years of leadership in RNA therapeutics research, having led research at Santaris for 11 years, and latterly at Roche after its acquisition of the former. Koch was a founder of Santaris’ predecessor companies Cureon and Exiqon.
BioMarin
GANESH VEDANTHAM
Adding to its new hires, BioMarin has appointed Ganesh Vedantham as senior vice president, technical development. With a strong scientific and leadership background, Vedantham has global experience in various chemistry, manufacturing and controls (CMC) functions across R&D and technical operations. Previously, he spent more than two decades at Amgen/Immunex in increasingly senior roles across the organisation.
Worldwide Clinical Trials
WOLFRAM DEMPKE
Worldwide Clinical Trials has appointed Wolfram Dempke as vice president, scientific solutions, haematology and oncology. Over a 30-year career in oncology, haematology and academia, Dempke has been responsible for clinical developments in ovarian cancer, lung cancer, and leukaemias and lymphomas. He has published five textbooks and many peer-reviewed papers, and continues to teach at Munich University.
Mogrify
TOM GRANEY
Mogrify has appointed Tom Graney as non-executive director. Graney has over 25 years’ experience in biopharma, including CFO at Vertex Pharmaceuticals, Ironwood Pharmaceuticals and Generation Bio. This follows a long career at Johnson & Johnson, including four years as worldwide vice president of finance and CFO of Ethicon. Most recently, he has been appointed CEO-CFO of Oxurion.
Amylyx
STÉPHANIE HOFFMANN-GENDEBIEN
Amylyx Pharmaceuticals has announced the appointment of Stéphanie Hoffmann-Gendebien as head, general manager in Europe, the Middle East and Africa (EMEA). Amylyx is incorporated in the Netherlands and is establishing a presence in Europe, and plans a future expansion into the Middle East and Africa markets. Hoffmann-Gendebien brings more than 20 years’ leadership experience in the pharmaceutical and biotechnology industries, having successfully led the launch of two orphan drugs in Europe and directed global market development launch planning for two additional orphan drugs. Previously, Hoffmann-Gendebien served as vice president, general manager, EMEA, at Clementia Pharmaceuticals. Prior to Clementia, she was the European director of strategic market development at Enobia Pharma (Alexion Pharmaceuticals) and held roles of increasing responsibility in Genzyme Europe (now Sanofi Genzyme). She serves on the board of directors at Secoya Technologies and volunteers with the European Organisation for Rare Diseases (EURORDIS). Most recently, she served as managing director and founding partner of GH Partners.
Versantis
KATHARINA STAUFER
Versantis has appointed Katharina Staufer as chief medical officer. A leading hepatologist, Staufer was most recently head of transplant medicine at University Hospital Bern and a consultant at the Medical University, Vienna. Staufer is a member of the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases.
Enthera Pharmaceuticals
ANTONIO SPEZIALE
Enthera Pharmaceuticals has appointed Antonio Speziale as chief medical officer to lead its clinical team and expand its pipeline. He brings 22 years’ experience in the pharmaceutical industry and joins Enthera from Galapagos, where he was translational medicine leader. Speziale previously held senior management positions at several other life sciences companies, including Novartis, Shire, Genzyme and at Wyeth.
Bausch Health
TOM VADAKETH
Tom Vadaketh is joining Bausch Health as chief financial officer. Vadaketh has more than 30 years’ financial leadership and experience, including nearly ten years in CFO roles at eResearch Technology, Cambrex Corporation and the Crosby Group. He also previously spent more than 20 years at Tyco International and Procter & Gamble, where he held roles of increasing responsibility.
MOMA Therapeutics
HANS BITTER
MOMA has appointed Hans Bitter as senior vice president and head, data science, a newly created role. Previously, Bitter served as senior vp, data sciences and chief data officer for oncology at bluebird bio, prior to which he was global head of oncology bioinformatics at the Novartis Institutes of Biomedical Research. He also held posts at Hoffman-LaRoche.
Xilio Therapeutics
TIMOTHY HUNT
Xilio has appointed Timothy Hunt to its executive team as chief culture and corporate affairs officer. He brings more than 20 years’ experience, including senior roles at Editas, Cubist Pharmaceuticals and Biogen. Hunt is a director of the non-profit organisation Life Sciences Cares and chair of the Ethics Committee of the American Society of Gene and Cell Therapy.
Centessa Pharmaceuticals
DAVID GRAINGER
David Grainger has been appointed by Centessa to the newly created role of chief innovation officer, joining its executive leadership team. Grainger joins from Medicxi, and was chairman and CEO of several of its portfolio companies. Previously, he was a venture partner with Index Ventures, before which he founded Funxional Therapeutics, Total Scientific and RxCelerate.
HexTransforma Healthcare
ASHLEY SMALLEY
HexTransforma Healthcare has appointed Ashley Smalley as vp strategy. He brings more than 20 years’ experience in strategy and consulting within the global healthcare sector. Previously he was senior director at Walgreens Boots Alliance, playing a significant part in its expansion into the US healthcare market with Walgreens. Smalley also held senior positions at Aviva, BUPA and AgeUK.
Noema Pharma
JEFFREY JONAS
Noema Pharma has appointed Jeffrey Jonas as independent chairman of the board of directors. Jonas has more than 25 years’ experience in the pharmaceutical and healthcare industries. He is former chief executive officer and current chief innovation officer of Sage Therapeutics, prior to which he held senior positions at Shire, ISIS Pharmaceuticals, Forest Laboratories and Upjohn Laboratories.
Fishawack Health
JONATHAN KOCH
Fishawack Health has appointed Jonathan Koch as its new CEO. Koch has spent his entire career in the healthcare sector, including nearly 12 years at Covance. Most recently, he served as senior vice president and CEO of Global Dental at Henry Schein, where he was responsible for the strategic direction and business performance of its largest healthcare division.
Fishawack Health
SHEENA AMIN-LIEBMAN
Sheena Amin-Liebman has joined Fishawack Health in the newly created role of Diversity and Inclusion (D&I) director. She has considerable experience in this field, having previously worked as the Diversity and Inclusion lead at Accenture Interactive, where she worked to develop a D&I strategy focused on delivering action and results that spanned the entire employee experience.
Lucid Group
ANDY BLACK
Andy Black, an experienced board-level executive for the life sciences industry, has joined Lucid Group as non-executive chairman of the board, to help inform Lucid Group’s growth and development strategy. Black, co-founder of Kinapse − an international consultancy to the life sciences industry − is a Professor of Practice at King’s College London, where he teaches entrepreneurship.
Ovid Health
MATTHEW SILK
Ovid Health has announced the appointment of Matthew Silk as associate director. Silk joins OVID from Ketchum, having spent most of his career working either for the NHS, or national health and care regulators, in and across Government departments and arms-length bodies. He was head of communications at the Human Tissue Authority for five years.
Ovid Health
SOPHIA AWAN
Adding to its hires, Sophia Awan has joined Ovid Health as operations manager, to support the agency’s growth strategy. Awan has over five years’ experience in start-up enterprises, delivering in operations, procurement and logistics roles. She is the group organiser for London Start-up Founders on meetup.com and is a co-facilitator for the East London Action for Happiness group.
90TEN
KATE PAXTON
90TEN has appointed Kate Paxton as its US head. Paxton has almost 30 years’ experience in agency communications and healthcare. Prior to 90TEN, she worked for JPA Health, where she designed and led campaigns for several biotech companies focused on oncology and rare diseases, and was with Ketchum for nearly 23 years, where she held multiple leadership positions.
Research Partnership
RICHARD GOOSEY
Research Partnership has appointed Richard Goosey as head of analytics. Goosey has over 40 years’ experience in marketing science, analytics and methodology. He is a Fellow of the Market Research Society and Royal Statistical Society, and an invited member of the EphMRA Forecasting Forum. Previously, he worked for Lundbeck, Roche and most recently Kantar Health for nine years.
Triducive
BETHAN JAMES
Triducive, the global market-shaping company, has boosted its team with two new appointments, reflecting its growth over the last two years. Bethan James joins as associate operations lead having recently graduated with a first class honours degree from the University of Portsmouth. James will provide support to improving business operations and systems to enhance the client experience.
Triducive
THOMAS SCOBLE
Also joining Triducive is Thomas Scoble, who is an experienced medical writer with expertise in supporting global brand communications in the areas of surgery, cardiovascular and general medicine markets. He is also an experienced scientific proofreader and editor, and will focus on writing content for communications that have a practical, dynamic application that inherently encourage behaviour change.
Mind+Matter
IAN RAY
Mind+Matter, an Ashfield Health Company, has announced the promotion of Ian Ray from associate creative to creative director. He will join the leadership team and will play a key role in shaping the future strategy and direction of the award-winning agency, which launched in January 2021 following the merger of Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing.
Mind+Matter
KESHA TANSEY
Also joining the leadership team at Mind+Matter is Kesha Tansey, who has been promoted to client director. The agency has bases in the US and the UK, with over 250 marketing specialists utilising the world of data and technology to create meaningful experiences, and growth since launch leading to more than 60 new hires globally.
Page & Page and Partners
JOSEPH NORMAN,
RUSSELL DOWLING, EMILY SWEET
Page & Page and Partners has announced three new full-time hires. Russell Dowling joins as creative artworker, Emily Sweet, as an additional medical writer who joins the Content team, and Joseph Norman, in a newly created marketing manager role. These new hires reflect the company’s growth over the last year and its relocation to London.